GENFIT Stock Euronext Paris
Stocks
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
||
| 13.91 EUR | 0.00% |
|
| Jul. 03 | Genfit soars on news of U.S. reimbursement for a product |  |
| Jul. 03 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
| Market Cap | 687M 786M 634M 586M 1.11B 74.94B 1.13B 7.57B 2.97B 36.92B 2.95B 2.89B 127B | P/E 2026 * |
72.5x | P/E 2027 * | 91.5x |
|---|---|---|---|---|---|
| Enterprise Value | 640M 732M 591M 546M 1.04B 69.83B 1.05B 7.06B 2.77B 34.4B 2.75B 2.69B 118B | EV / Sales 2026 * |
6.73x | EV / Sales 2027 * | 5.29x |
| Free-Float |
86.88% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 2019-09-15 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 2021-04-21 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 2025-11-26 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 2021-03-03 | |
| Chairman | 70 | 2017-06-15 | |
| Director/Board Member | 54 | 1999-09-14 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.58% | +3.79% | +4.16% | +11.62% | 50.44B | |
| -2.22% | -1.64% | +385.40% | +586.81% | 40.63B | |
| -0.54% | +0.91% | +25.57% | -5.28% | 34.88B | |
| -1.36% | -3.48% | +17.88% | +55.14% | 33.67B | |
| +1.21% | -0.79% | +4.46% | +35.18% | 26.29B | |
| -1.81% | +0.94% | - | - | 17.11B | |
| +0.51% | -4.75% | +63.97% | +122.60% | 15.29B | |
| -9.37% | -29.97% | +37.45% | +39.42% | 10.62B | |
| +0.23% | -0.26% | +15.51% | +21.54% | 13.74B | |
| Average | -1.30% | -2.12% | +69.30% | +108.38% | 26.96B | |
| Weighted average by Cap. | -0.70% | -0.03% | +84.54% | +131.30% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 95.2M 109M 87.81M 81.1M 154M 10.38B 156M 1.05B 412M 5.11B 409M 400M 17.58B | 119M 136M 110M 102M 193M 13B 196M 1.31B 516M 6.41B 512M 501M 22.02B |
| Net income | 18.63M 21.3M 17.18M 15.87M 30.11M 2.03B 30.62M 205M 80.62M 1B 79.96M 78.22M 3.44B | 33.33K 38.1K 30.74K 28.39K 53.88K 3.63M 54.78K 367K 144K 1.79M 143K 140K 6.15M |
| Net Debt | -46.87M -53.58M -43.23M -39.93M -75.76M -5.11B -77.03M -517M -203M -2.52B -201M -197M -8.65B | -56.87M -65.02M -52.46M -48.45M -91.93M -6.2B -93.48M -627M -246M -3.05B -244M -239M -10.5B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
